Adam Feuerstein…make me chuckle some more! Question: Who must agree to a PIII protocol, including all modes and methods for endpoint analysis? Shhhh…it’s a quiet period.
Adam Feuerstein…make me chuckle some more! Question: Are all endpoints usually presented on a poster? Shhhh…it’s a quiet period.
That's it? Yes, we have a problem! Definitely...Ha!
Insmed stated that the reason they would not comment on the data presented was (drum roll please) was "The company was unable to discuss the Arikace phase III results because the company was in a self-imposed quiet period ahead of third-quarter financial results on Nov. 5.For all the jerks who have not read or UNDERSTAND the poster the story or other sources please Shtthefkup! Sold half
1) PIII trial protocols are reviewed and approved in consultation with the regulatory agency. To suggest something nefarious in the design of the trial endpoints is suspicious and not very probable.
2) Posters do not generally address all data and endpoints of a trial. To suggest that something is wrong because data is not present is as insightful as saying everything is wonderful because all the data is presented without examination.
3) The article title is not what he says.
4) Evidently we have the EMEA submission expected next year...where does that come from?
If you look at his various "articles" he seems to be the guy at the Street that does their hack jobs in the pharma area. Virtually everything he's written is negative. This is why The Street and its founder, Cramer, have no credibility anymore. They are just hedge fund shills.